ERT’s Trial Oversight solution shortlisted for clinical trial award

Published: 22-Sep-2017
Regulatory Digital

ERT, a global data and technology company that minimises uncertainty and risk in clinical trials, announced that ERT Trial Oversight — its centralised, cloud-based clinical trial management solution — has been named a finalist for the 2017 Scrip Best Sponsor-Focused Technological Development in Clinical Trials Award

The ERT Trial Oversight integrates trial data from any source to put real-time, actionable data in the hands of sponsors and their CRO partners.

This enhanced visibility enables more proactive decisions, minimises risks and fosters greater collaboration among trial stakeholders.

Mike Ward, Global Director of Content, Scrip said: “The 2017 Scrip Awards provides the biopharma industry with an opportunity to acknowledge its highest achievers across the entire value chain and to recognise both company and individual achievements. We are pleased to announce ERT as a finalist for its advancements in improving clinical trial efficiencies for sponsors and CROs.”

By addressing these critical areas within the clinical development process, ERT helps sponsors and CROs bring new treatments to market faster.

James Corrigan, President and CEO of ERT, said: “We are honoured to be named a Scrip Award finalist and to be part of this distinguished group of organisations being recognised for their innovation, dedication and hard work in advancing drug development.

“This nomination is a reflection of our employees’ unwavering commitment to delivering innovative and practical solutions that our customers can have confidence in as they bring life-changing medical treatments to the patients who need them.”

Award winners will be announced in London on 29 November.

  • Companies:
  • ERT
See more

You may also like

Regulatory

ERT receives sixth consecutive award for outstanding customer service

Read more
Remains committed to exceeding expectations, driving high satisfaction

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Neurolentech partners with Kaerus Bioscience to advance neurodevelopmental disorder research Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes
  3. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  4. Simplifying technology transfer to get drugs to market faster Albina Pace, Director of Life Science Sales, Europe, at Emerson, outlines common technology transfer challenges and explains how process knowledge management software can help to significantly reduce the time-to-market for new treatments
  5. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Regulatory

ERT receives sixth consecutive award for outstanding customer service

Remains committed to exceeding expectations, driving high satisfaction
Research & Development

Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool

The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Research & Development

Neurolentech partners with Kaerus Bioscience to advance neurodevelopmental disorder research

Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes
Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Subscribe now